Cargando…
EGFR敏感突变NSCLC患者的最佳治疗模式探讨
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in non-small cell lung cancer (NSCLC) patients, it is still controversial about how to combine EGFR-TKI with chemotherapy and other targeted drugs. We have made a summary on the current therapeutic...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999843/ https://www.ncbi.nlm.nih.gov/pubmed/25676406 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.11 |